CLAIM CARD
Mechanistically, the reduction in TBR suggests CGM provides actionable real-time data that helps patients and clinicians avoid overtreatment and insulin stacking, which is particularly crucial in CKD where drug clearance is impaired. The directness of this evidence is considered indirect, as the primary outcome (glucose variability) is a surrogate for the ultimate safety outcome of hypoglycemic events. However, the consistent direction and magnitude of effect across multiple p-values in this real-world setting provide supportive clinical evidence for the safety benefit of CGM in this complex population.
Evidence grade: exploratory
Contradiction status: none
Publication: becb4785-6244-41cd-ba08-c47e58dca346
Provenance: Derivation Web chain
Citation Support
source_1Sidki 2026source_2Gravesteijn 2023source_3Lu 2021source_4Lee 2020source_5Franceschi 2026